This startup develops AI-powered digital twins of patients to simulate drug effects and optimize clinical trials. Their platform uses machine learning to identify effective treatments for specific diseases, accelerating drug discovery and development.
Funding
$23M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery and development processes are slow, expensive, and often fail to identify effective treatments due to the complexity of human biology and disease mechanisms. Existing methods struggle to accurately predict drug efficacy and personalize treatment strategies for specific patient populations.
Solution
Aitia develops Gemini Digital Twins, which are AI-powered, in silico models of human disease built from multi-omic patient data. These digital twins leverage causal AI to reverse-engineer the biological mechanisms of disease, revealing novel intervention points for drug discovery. The platform simulates drug effects on individual patients, enabling the identification of effective treatments and the optimization of clinical trials. By generating precise understandings of human disease, Aitia accelerates the discovery and development of targeted therapies, addressing unmet medical needs in areas such as oncology and neurodegenerative diseases.
Target Audience
Aitia's primary customers are pharmaceutical companies and research institutions involved in drug discovery and development, seeking to accelerate the identification of effective treatments and personalize therapeutic strategies.
Features
- Causal AI reverse-engineering engine to model disease mechanisms
- Integration of multi-omic patient data (genomic, proteomic, etc.) for comprehensive disease modeling
- In silico simulation of drug effects on individual patients
- Identification of novel therapeutic targets and biomarkers
- Prediction of drug efficacy and patient response
- Optimization of clinical trial design and patient stratification
- Partnered programs in oncology and neurodegenerative diseases